CBAY CymaBay Therapeutics Inc Analyst Estimates & Rating

This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023.

The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.

CymaBay Therapeutics’ Lead Drug Candidate Hits Main Goal In Pivotal Study For Liver Damage

There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” CBAY shares. JonesTrading analyst Sean Kim PhD reiterated a Buy rating on CymaBay Therapeutics (CBAY – Research Report) today and set a price target of $19.00. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar, including clinical trials targeting market expansion, and for working capital and general corporate purposes. High-growth stocks tend to represent the technology, healthcare, and communications sectors.

Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. The technique has proven to be very useful for finding positive surprises. Shares of CymaBay Therapeutics Inc. are down 77% in premarket trading after the biopharmaceutical company ended two studies and halted a third for its experimental drug seladelpar.

Smartsheet, Kroger, Lantronix And Other Big Stocks Moving Higher On Friday

That could help differentiate CymaBay’s drug from Intercept’s approved medicine, Ocaliva, and another experimental drug from Genfit called elafibranor. Shares of CBAY stock surged for a second day Friday as analysts compared CymaBay Therapeutics’ (CBAY) experimental liver-disease treatment to rivals from Intercept Pharmaceuticals (ICPT) and Genfit (GNFT). CBAY gained 23% premarket on Thursday after the company released positive results from a late-stage study of seladelpar, its investigational treatment for the rare … CymaBay Therapeutics’ stock was trading at $6.27 on January 1st, 2023. Since then, CBAY shares have increased by 169.7% and is now trading at $16.91.

CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. 12 Wall Street research analysts have issued 1-year target prices for CymaBay Therapeutics’ stock. Their CBAY share price forecasts range from $12.00 to $33.00. On average, they predict the company’s stock price to reach $19.18 in the next twelve months. This suggests a possible upside of 13.4% from the stock’s current price.

The average twelve-month price prediction for CymaBay Therapeutics is $19.18 with a high price target of $33.00 and a low price target of $12.00. This press release contains forward-looking statements, including statements relating to CymaBay’s expectations regarding the timing of the closing of the public offering and anticipated use of proceeds. These statements are subject to significant risks and uncertainties and actual results could differ materially agency cost meaning from those projected. CymaBay cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to the satisfaction of customary closing conditions related to the public offering. There can be no assurance that CymaBay will be able to complete the public offering on the anticipated terms, or at all.

In a report released on September 8, SVB Securities also maintained a Buy rating on the stock with a $20.00 price target. According to 12 analysts, the average rating for CBAY stock is “Strong Buy.” The 12-month stock price forecast is $19.55, which is an increase of 15.82% from the latest price. For the third day in a row, shares of CymaBay Therapeutics (CBAY 0.71%) enjoyed a very healthy gain in price. That came on the announcement of a capital-raising effort by the company. Ultimately, CymaBay stock closed Monday more than 5% higher; by comparison, the S&P 500 index managed only a 0.7% increase. According to analysts, CymaBay Therapeutics’s stock has a predicted upside of 53.56% based on their 12-month price targets.

• CBAY’s beta can be found in Trading Information at the top of this page.
• According to analysts, CymaBay Therapeutics’s stock has a predicted upside of 53.56% based on their 12-month price targets.
• Style is an investment factor that has a meaningful impact on investment risk and returns.
• Get this delivered to your inbox, and more info about our products and services.

Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. According to the issued ratings of 12 analysts in the last year, the consensus rating for CymaBay Therapeutics stock is Buy based on the current 11 buy ratings and 1 strong buy rating for CBAY.

Investor Services

Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat’s FREE daily newsletter.

Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of CBAY stock can currently be purchased for approximately $16.91. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.

Services

The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Plus, CBAY info will be updated daily in your Zacks.com Portfolio Tracker – also free.

Monday morning, CymaBay announced that it had floated a $150 million issue of common stock and warrants. The clinical-stage biotech said it intends to grant the offering’s underwriting syndicate, led by BTIG, a 30-day option to purchase an additional 15% of the amount of shares in the issue. These shares include stock that undergirds the pre-funded warrants. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Financial Performance

View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts. CymaBay said that the funds raised will be channeled into the development of its investigational drug seladelpar, which targets a rare chronic inflammatory liver affliction called primary biliary cholangitis (PBC). The monies will be used for clinical trials, the company’s working capital, and “general corporate purposes.” At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI. Kim PhD covers the Healthcare sector, focusing on stocks such as Clearside Biomedical, EyePoint Pharmaceuticals, and CymaBay Therapeutics.

Get this delivered to your inbox, and more info about our products and services. Additional data presented at The International Liver Congress™ 2023 show clinical risk factors for PBC disease progression present in a broader population of UDCA-treated PBC patients Preclinical data… Evaluates seladelpar 10 mg vs. placebo for alkaline phosphatase normalization at 52 weeks Patients enroll with alkaline phosphatase levels between 1- and 1.67-times upper limit of normal NEWARK, Calif… The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat’s FREE daily newsletter.

The S&P 500 is highly concentrated on the largest tech stocks. But there are other broad indexes with even heavier concentration to tech giants. If your trading operation lacks a cadre of PhDs to crunch data like Renaissance Technologies or D.E. Two abstracts focus on the unique mechanism of action of seladelpar; a third focuses on characterizing patient risk of PBC disease progression NEWARK, Calif. , June 7, 2023 /PRNewswire/ — CymaBay The…

Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply. Compare
CBAY’s historical performance
against its industry peers and the overall market. Our Quantitative https://1investing.in/ Research team models direct competitors or comparable companies
from a bottom-up perspective to find companies describing their business in a
similar fashion. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries.

According to TipRanks, Kim PhD has an average return of 7.8% and a 40.91% success rate on recommended stocks. Analysts like CymaBay Therapeutics more than other Medical companies. The consensus rating for CymaBay Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Notably, CymaBay stock has a best-possible Relative Strength Rating of 99, according to IBD Digital. This puts its shares in the top 1% of all stocks when it comes to 12-month performance. On a year-to-date basis, CBAY stock has soared more than 159%.

CymaBay Therapeutics’ stock is owned by a variety of institutional and retail investors. Insiders that own company stock include Charles Mcwherter, Daniel Menold, Dennis D Kim, Paul T Quinlan and Sujal Shah. CymaBay Therapeutics saw a decline in short interest in August. As of August 31st, there was short interest totaling 8,960,000 shares, a decline of 21.1% from the August 15th total of 11,350,000 shares. Based on an average daily trading volume, of 2,410,000 shares, the days-to-cover ratio is presently 3.7 days.